| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-04-12 |
GSK (UK) Orchard Therapeutics (UK) Molmed (Italy) |
approved and investigational rare disease gene therapies including Strimvelis® |
adenosine deaminase severe combined immunodeficiency (ADA-SCID), metachromatic leukodystrophy (MLD), Wiskott Aldrich syndrome (WAS) , beta thalassaemia, mucopolysaccharidosis type 1 (MPS1 or Hurler syndrome), chronic granulomatous disease (CGD), globoid cell leukodystrophy (GLD) |
pipeline acquisition |
Rare diseases - Genetic diseases |
Pipeline acquisition |
| 2018-03-28 |
Celgene (USA - NJ) Bluebird bio (USA - MA) |
product candidates targeting B-cell maturation antigen (BCMA) including bb2121 and bb21217 |
multiple myeloma |
collaboration - development |
Cancer - Oncology |
Development agreement |
| 2018-03-26 |
Nanomedsyn (France) Shire (UK - USA) |
- enzyme replacement therapy using AMFA (recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues)
|
undisclosed lysosomal disease |
R&D - research |
Rare diseases - Genetic diseases |
Research agreement |
| 2018-03-21 |
Alnylam Pharmaceuticals (USA - MA) Regeneron Pharmaceuticals (USA - NY) |
RNAi therapeutics |
NASH (non-alcoholic steatohepatitis) and potentially other related diseases |
R&D - research |
Hepatic diseases - Liver diseases |
Research agreement |
| 2018-02-20 |
Voyager Therapeutics (USA - MA) Abbvie (USA - IL) |
vectorized antibodies directed against tau |
Alzheimer’s disease and other tau-related neurodegenerative diseases |
development - commercialisation |
Neurodegenerative diseases |
Development agreement |
| 2018-02-15 |
Oxford Biomedica (UK) Bioverativ (USA - CA) |
lentiviral vectors to treat haemophilia |
hemophilia |
licensing - collaboration |
Rare diseases - Genetic diseases - Hematological diseases |
Licensing agreement |
| 2018-02-05 |
Orchard Therapeutics (UK) |
member of the scientific advisory board |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-02-05 |
Oryzon Genomics (Spain) |
member of the scientific advisory board |
|
nomination |
Cancer - Oncology - Neurodegenerative diseases |
Nomination |
| 2018-01-31 |
Aicuris (Germany) Merck&Co (USA) |
investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246) |
treatment and prevention of HCMV infection in transplant recipients |
licensing - development - commercialisation |
Infectious diseases - Transplantation |
Milestone |
| 2018-01-30 |
AB Biosciences (USA - MA) Shire (UK - USA) |
pan receptor interacting molecule (PRIM) program |
|
licensing - development - commercialisation |
Autoimmune diseases |
Licensing agreement |
| 2018-01-25 |
Synpromics (UK) UCL Great Ormond Street Institute of Child Health (UK) |
synthetic tissue-specific promoters for use in the specialised cells of the immune system |
pathologies affecting the haematopoietic system |
research - development |
Cancer - Oncology - Immunological diseases |
Development agreement |
| 2018-01-22 |
Sillajen (Republic of Korea) ABL Europe (France) |
Pexa-Vec (formerly JX-594), JX-970 |
|
production - manufacturing |
Technology - Services - Cancer - Oncology |
Production agreement |
| 2018-01-18 |
Gilead Sciences (USA - CA) Pfizer (USA - NY) |
Yescarta™ (axicabtagene ciloleucel) and utomilumab large B-cell lymphoma |
refractory large B-cell lymphoma |
clinical research |
Cancer - Oncology |
Clinical research agreement |
| 2018-01-17 |
Homology Medicines (USA - MA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-01-17 |
Synpromics (UK) |
vice-president |
|
nomination |
Technology - Services |
Nomination |
| 2018-01-10 |
Ipsen (France) |
vice-president |
|
nomination |
Cancer - Oncology - Rare diseases - Neurological diseases |
Nomination |
| 2018-01-10 |
Aimmune Therapeutics (USA - CA) Archer Daniels Midland (USA -IL) |
peanuts and tree nuts and exclusively supplies the starting material for AR101 |
peanut allergy |
production - manufacturing
|
Allergic diseases |
Production agreement |
| 2018-01-10 |
Basilea Pharmaceutica (Switzerland) Pfizer (USA - NY) |
Cresemba® (isavuconazole) |
life-threatening invasive mold infections |
licensing |
Infectious diseases |
Licensing agreement |
| 2018-01-08 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
bispecific antibodies and monoclonal antibodies including REGN3500, dupilumab and programmed cell death protein 1 (PD-1) inhibitor cemiplimab |
|
collaboration - development - commercialisation |
Allergic diseases - Cancer - Oncology |
Collaboration agreement |
| 2018-01-08 |
Five Prime Therapeutics (USA - CA) BMS (USA - NY) |
immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways |
|
R&D - development - commercialisation |
Cancer - Oncology |
Milestone |
